The epidemiology of atopic dermatitis in older adults: A population-based study in the United Kingdom.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
04
2021
accepted:
21
09
2021
entrez:
6
10
2021
pubmed:
7
10
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Atopic dermatitis is known to be common among children, but there are few studies examining the epidemiology across the life course. In particular, there is a paucity of data on atopic dermatitis among older adults. To evaluate participant characteristics, patterns of disease activity and severity, and calendar trends in older adult atopic dermatitis in comparison to other age groups in a large population-based cohort. This was a cohort study of 9,154,936 individuals aged 0-99 years registered in The Health Improvement Network, a database comprised of electronic health records from general practices in the United Kingdom between 1994 and 2013. Atopic dermatitis was defined by a previously validated algorithm using a combination of at least one recorded atopic dermatitis diagnostic code in primary care and two atopic dermatitis therapies recorded on separate days. Cross-sectional analyses of disease prevalence were conducted at each age. Logistic mixed effect regression models were used to identify predictors of prevalent disease over time among children (0-17 years), adults (18-74 years), and older adults (75-99 years). Physician-diagnosed atopic dermatitis was identified in 894,454 individuals with the following proportions in each age group: 18.3% of children, 7.7% of adults, and 11.6% of older adults. Additionally, atopic dermatitis prevalence increased across the 2-decade period (beta from linear regression test for trend in the change in proportion per year = 0.005, p = 0.044). In older adults, atopic dermatitis was 27% less common among females (adjusted OR 0.73, 95% CI 0.70-0.76) and was more likely to be active (59.7%, 95% CI 59.5-59.9%) and of higher severity (mean annual percentage with moderate and severe disease: 31.8% and 3.0%, respectively) than in other age groups. In a large population-based cohort, the prevalence of physician-diagnosed atopic dermatitis has increased throughout adulthood and was most common among males age 75 years and above. Compared to children ages 0-17 and adults ages 18-74, older adult atopic dermatitis was more active and severe. Because the prevalence of atopic dermatitis among older adults has increased over time, additional characterization of disease triggers and mechanisms and targeted treatment recommendations are needed for this population.
Sections du résumé
BACKGROUND
Atopic dermatitis is known to be common among children, but there are few studies examining the epidemiology across the life course. In particular, there is a paucity of data on atopic dermatitis among older adults.
OBJECTIVE
To evaluate participant characteristics, patterns of disease activity and severity, and calendar trends in older adult atopic dermatitis in comparison to other age groups in a large population-based cohort.
METHODS
This was a cohort study of 9,154,936 individuals aged 0-99 years registered in The Health Improvement Network, a database comprised of electronic health records from general practices in the United Kingdom between 1994 and 2013. Atopic dermatitis was defined by a previously validated algorithm using a combination of at least one recorded atopic dermatitis diagnostic code in primary care and two atopic dermatitis therapies recorded on separate days. Cross-sectional analyses of disease prevalence were conducted at each age. Logistic mixed effect regression models were used to identify predictors of prevalent disease over time among children (0-17 years), adults (18-74 years), and older adults (75-99 years).
RESULTS
Physician-diagnosed atopic dermatitis was identified in 894,454 individuals with the following proportions in each age group: 18.3% of children, 7.7% of adults, and 11.6% of older adults. Additionally, atopic dermatitis prevalence increased across the 2-decade period (beta from linear regression test for trend in the change in proportion per year = 0.005, p = 0.044). In older adults, atopic dermatitis was 27% less common among females (adjusted OR 0.73, 95% CI 0.70-0.76) and was more likely to be active (59.7%, 95% CI 59.5-59.9%) and of higher severity (mean annual percentage with moderate and severe disease: 31.8% and 3.0%, respectively) than in other age groups.
CONCLUSION
In a large population-based cohort, the prevalence of physician-diagnosed atopic dermatitis has increased throughout adulthood and was most common among males age 75 years and above. Compared to children ages 0-17 and adults ages 18-74, older adult atopic dermatitis was more active and severe. Because the prevalence of atopic dermatitis among older adults has increased over time, additional characterization of disease triggers and mechanisms and targeted treatment recommendations are needed for this population.
Identifiants
pubmed: 34614025
doi: 10.1371/journal.pone.0258219
pii: PONE-D-21-12334
pmc: PMC8494374
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0258219Subventions
Organisme : Wellcome Trust
ID : 205039/Z/16/Z
Pays : United Kingdom
Organisme : NIAMS NIH HHS
ID : K23 AR073915
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001870
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG000246
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: KA is a consultant for TARGET RWE, a company developing an atopic disease research registry, and her institution receives investigator-initiated grants from Pfizer and Cosmetique Active Internacional SNC. DJM receives funding to the University of Pennsylvania from Valeant for studies not directly related to this manuscript. He receives consulting funds from Leo, Sanofi, and Pfizer for topics related to atopic eczema but not this manuscript. No other disclosures were reported. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
BMJ. 2018 May 23;361:k1786
pubmed: 29792314
J Invest Dermatol. 2017 Aug;137(8):1655-1662
pubmed: 28428130
J Allergy Clin Immunol Pract. 2020 Jan;8(1):248-257.e16
pubmed: 31479767
Eur Respir J. 1995 Mar;8(3):483-91
pubmed: 7789502
Ann Allergy Asthma Immunol. 2018 Jun;120(6):654-660.e1
pubmed: 29630929
Br J Dermatol. 2018 Mar;178(3):768-775
pubmed: 28865094
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1180-7
pubmed: 25363318
JAMA Dermatol. 2020 Jun 1;156(6):659-667
pubmed: 32320001
J Allergy Clin Immunol. 2020 Feb;145(2):563-571.e8
pubmed: 31757515
JAMA Dermatol. 2020 Nov 1;156(11):1240-1245
pubmed: 32822481
J Invest Dermatol. 2019 Mar;139(3):583-590
pubmed: 30389491
Br J Dermatol. 2004 Jan;150(1):103-10
pubmed: 14746623
J Allergy Clin Immunol. 2019 Sep;144(3):710-719
pubmed: 31260715
Geriatr Gerontol Int. 2016 Mar;16 Suppl 1:75-86
pubmed: 27018286
Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):393-401
pubmed: 17066486
Inform Prim Care. 2011;19(4):251-5
pubmed: 22828580
Br J Dermatol. 1998 Jul;139(1):73-6
pubmed: 9764151
Med Clin North Am. 2020 Jan;104(1):157-176
pubmed: 31757234
J Allergy Clin Immunol. 2013 Nov;132(5):1132-8
pubmed: 24094544
J Allergy Clin Immunol. 2019 May;143(5):1821-1829
pubmed: 30576754
Clin Exp Allergy. 2021 Mar;51(3):471-482
pubmed: 33179341
Ann Intern Med. 2019 Mar 5;170(5):354-356
pubmed: 30508419
Br J Dermatol. 2010 May;162(5):964-73
pubmed: 20331459
Br J Dermatol. 2020 Jan;182(1):47-54
pubmed: 30895603
Lancet. 2020 Aug 1;396(10247):345-360
pubmed: 32738956
Br J Gen Pract. 2010 Mar;60(572):e128-36
pubmed: 20202356
Drugs Aging. 2020 Mar;37(3):149-160
pubmed: 32086792
Int Arch Allergy Immunol. 2012;157(4):372-8
pubmed: 22122980
J Clin Med. 2015 May 18;4(5):979-97
pubmed: 26239460
PLoS One. 2012;7(7):e39803
pubmed: 22808063
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1509-1515
pubmed: 28516452
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2346-2352
pubmed: 32163633
Lancet Digit Health. 2019 May 20;1(2):e63-e77
pubmed: 31650125
Eur Respir J. 2015 Aug;46(2):364-74
pubmed: 25537562